If approved, Johnson & Johnson would pay $8.9 billion to resolve all current and future claims in its ongoing talc litigation.
Johnson & Johnson (J&J) announced its plans to pay $8.9 billion to resolve litigation regarding its cosmetic talc powder. The litigation, which alleges that the company’s talcum powder was linked to ovarian cancer and mesothelioma, were brought forth by lawyers representing nearly 70,000 affected individuals. In a public statement released on April 4, 2023, the company reiterated that neither this re-filing nor the original filing was an admission of wrongdoing or an indication that the company believed its talcum powder products are unsafe.
J&J’s subsidiary, LTL Management, has re-filed for voluntary Chapter 11 bankruptcy protection to obtain approval of a reorganization plan to enable the $8.9 billion payment, which would be payable over 25 years. This payment represents a $6.9 billion increase to the company’s original commitment in October 2021, when it initially filed for bankruptcy.
“The [c]ompany continues to believe that these claims are specious and lack scientific merit,” said Erik Haas, worldwide vice-president of Litigation, J&J, in the release. “However, as the Bankruptcy Court recognized, resolving these cases in the tort system would take decades and impose significant costs on LTL and the system, with most claimants never receiving any compensation. Resolving this matter through the proposed reorganization plan is both more equitable and more efficient, allows claimants to be compensated in a timely manner, and enables the [c]ompany to remain focused on [its] commitment to profoundly and positively impact health for humanity.”
Source: Johnson & Johnson
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.